Get the Stockscreener App
63.47
1.50%
0.94
Dexcom Inc stock is traded at $63.47, with a volume of 2.26M.
It is up +1.50% in the last 24 hours and down -8.32% over the past month.
DexCom designs and commercializes continuous glucose monitoring systems for diabetic patients. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to provide integration with insulin pumps from Insulet and Tandem for automatic insulin delivery.
See More
Previous Close:
$62.53
Open:
$62.565
24h Volume:
2.26M
Relative Volume:
0.36
Market Cap:
$24.75B
Revenue:
$4.30B
Net Income/Loss:
$571.50M
P/E Ratio:
44.43
EPS:
1.4285
Net Cash Flow:
$570.80M
1W Performance:
+5.38%
1M Performance:
-8.32%
6M Performance:
-27.03%
1Y Performance:
-18.73%
1-Day Range:
$62.23
$63.95
1-Week Range:
$60.07
$64.00
52-Week Range:
$54.11
$93.25
Dexcom Inc Stock (DXCM) Company Profile
Name
Dexcom Inc
Sector
Industry
Phone
(858) 200-0200
Address
6340 SEQUENCE DRIVE, SAN DIEGO, CA
Compare DXCM with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
DXCM
Dexcom Inc
|
63.47 | 24.39B | 4.30B | 571.50M | 570.80M | 1.4285 |
|
ABT
Abbott Laboratories
|
128.90 | 223.51B | 43.84B | 13.90B | 6.92B | 7.9725 |
|
BSX
Boston Scientific Corp
|
101.58 | 149.67B | 19.35B | 2.78B | 3.82B | 1.8696 |
|
SYK
Stryker Corp
|
371.18 | 142.37B | 24.38B | 2.94B | 4.07B | 7.6159 |
|
MDT
Medtronic Plc
|
105.33 | 134.64B | 34.76B | 4.79B | 5.21B | 3.7017 |
|
EW
Edwards Lifesciences Corp
|
86.67 | 50.34B | 5.88B | 1.34B | 799.60M | 2.3489 |
Dexcom Inc Stock (DXCM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-25-25 | Initiated | Evercore ISI | In-line |
| Oct-21-25 | Resumed | Stifel | Buy |
| Sep-08-25 | Downgrade | Oppenheimer | Outperform → Perform |
| Aug-21-25 | Initiated | Argus | Buy |
| Jun-16-25 | Initiated | Truist | Buy |
| May-30-25 | Initiated | Goldman | Buy |
| Apr-10-25 | Initiated | Mizuho | Outperform |
| Feb-03-25 | Upgrade | Redburn Atlantic | Neutral → Buy |
| Jan-16-25 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Jul-26-24 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-26-24 | Downgrade | Robert W. Baird | Outperform → Neutral |
| May-30-24 | Initiated | Redburn Atlantic | Neutral |
| Mar-12-24 | Initiated | RBC Capital Mkts | Outperform |
| May-30-23 | Resumed | Morgan Stanley | Equal-Weight |
| Apr-17-23 | Upgrade | Raymond James | Outperform → Strong Buy |
| Mar-29-23 | Initiated | UBS | Buy |
| Jan-26-23 | Initiated | Wolfe Research | Outperform |
| Oct-18-22 | Initiated | Barclays | Equal Weight |
| Oct-12-22 | Initiated | Jefferies | Buy |
| Jul-15-22 | Initiated | Bernstein | Outperform |
| Mar-02-22 | Resumed | BofA Securities | Buy |
| Feb-03-22 | Upgrade | BTIG Research | Neutral → Buy |
| Jan-19-22 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Jan-07-22 | Upgrade | Guggenheim | Neutral → Buy |
| Oct-18-21 | Downgrade | Guggenheim | Buy → Neutral |
| Jul-21-21 | Resumed | Cowen | Outperform |
| May-28-21 | Upgrade | Wells Fargo | Underweight → Equal Weight |
| May-25-21 | Initiated | Barclays | Overweight |
| Apr-15-21 | Initiated | Atlantic Equities | Overweight |
| Jan-06-21 | Upgrade | UBS | Neutral → Buy |
| Oct-02-20 | Downgrade | Wells Fargo | Equal Weight → Underweight |
| May-27-20 | Reiterated | Piper Sandler | Overweight |
| May-14-20 | Initiated | Wells Fargo | Equal Weight |
| Mar-05-20 | Initiated | Citigroup | Buy |
| Nov-07-19 | Reiterated | Canaccord Genuity | Buy |
| Nov-07-19 | Upgrade | Guggenheim | Neutral → Buy |
| Oct-23-19 | Initiated | Stifel | Buy |
| Nov-28-18 | Initiated | UBS | Neutral |
| Oct-19-18 | Upgrade | Goldman | Sell → Neutral |
| Sep-12-18 | Upgrade | Northland Capital | Under Perform → Market Perform |
| Aug-02-18 | Reiterated | Canaccord Genuity | Buy |
| Jul-02-18 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Jun-08-18 | Upgrade | JP Morgan | Neutral → Overweight |
| May-11-18 | Initiated | BofA/Merrill | Buy |
| May-03-18 | Reiterated | Canaccord Genuity | Buy |
| Apr-04-18 | Initiated | Goldman | Sell |
| Apr-04-18 | Initiated | Guggenheim | Neutral |
| Mar-23-18 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Jan-04-18 | Downgrade | Northland Capital | Market Perform → Under Perform |
| Sep-28-17 | Reiterated | Wedbush | Outperform |
View All
Dexcom Inc Stock (DXCM) Latest News
DXCM CLASS ACTION FILED: Kessler Topaz Meltzer & Check, LLP Reminds Investors - GlobeNewswire Inc.
Levi & Korsinsky Urges DexCom, Inc. (DXCM) Shareholders to Act Before Lead Plaintiff Deadline December 26, 2025 - Stockhouse
DXCM Shareholders Have Opportunity to Lead DexCom, Inc. Class Action Lawsuit – Contact Bronstein, Gewirtz and Grossman, LLC Today! - ACCESS Newswire
Global Retirement Partners LLC Takes $472,000 Position in DexCom, Inc. $DXCM - Defense World
DXCM DEADLINE ALERT: ROSEN, A LEADING LAW FIRM, Encourages DexCom, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – DXCM - GlobeNewswire Inc.
2025-11-29 | Securities Fraud Class Action Filed Against DexCom, Inc. (DXCM)Levi & Korsinsky Reminds Investors of December 26, 2025 | NDAQ:DXCM | Press Release - Stockhouse
DXCM Investor Alert: A Securities Fraud Class Action Lawsuit Has Been Filed Against DexCom, Inc. (DXCM) - PR Newswire
Berry Wealth Group LP Takes $251,000 Position in DexCom, Inc. $DXCM - Defense World
DexCom, Inc. (NASDAQ:DXCM) Receives Consensus Recommendation of “Moderate Buy” from Analysts - Defense World
DXCM Investors Have Opportunity to Lead DexCom, Inc. Class Action Lawsuit – Contact Bronstein, Gewirtz and Grossman, LLC Today! - ACCESS Newswire
Synopsys, Inc. Sued for Securities Law Violations - GlobeNewswire Inc.
DXCM Investors Have Opportunity to Lead DexCom, Inc. Securities Fraud Lawsuit with the Schall Law Firm - GlobeNewswire
DXCM SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that DexCom, Inc. Stockholders Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Here’s Why Dexcom (DXCM) Traded Down in Q3 - Insider Monkey
DXCM DEADLINE ALERT: ROSEN, GLOBAL INVESTOR COUNSEL, Encourages DexCom, Inc. Investors to ... - Bakersfield.com
Artificial Intelligence in Remote Patient Monitoring Market Projected to Reach $14.51 Billion by 2032, Growing at a CAGR of 27.52% - GlobeNewswire Inc.
Evercore ISI Begins Coverage on DexCom (NASDAQ:DXCM) - Defense World
DXCM SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that DexCom, Inc. Shareholders Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
DXCM Deadline: DXCM Investors Have Opportunity to Lead DexCom, Inc. Securities Fraud Lawsuit - Morningstar
DXCM INVESTORS: Contact Kirby McInerney LLP About Securities Class Action Lawsuit On Behalf of DexCom, Inc. - Business Wire
DexCom (DXCM): Positive Outlook Amid Medicare Payment Report - GuruFocus
Labaton Keller Sucharow LLP Announces Expanded Securities Class Action Lawsuit Filed Against DexCom, Inc. and Certain Executives - Business Wire
DXCM Class Action Alert: Kessler Topaz Meltzer & Check, LLP Reminds DexCom, Inc. (DXCM) Shareholders of Securities Fraud Class Action Lawsuit Deadline - NewMediaWire
DXCM INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC - GlobeNewswire
DexCom, Inc. (DXCM) Investors: December 26, 2025 Filing Deadline in Securities Class ActionContact Lieff Cabraser - ACCESS Newswire
GlucoGuard a Division of American Diversified Holdings (ADHC) Successfully Submits Level 2 App Integration Through Dexcom's Developer Partner Program - TradingView
Morgan Stanley, Truist Cautious on DexCom (DXCM) Cites Weaker Gross Margins, Modest Q3 Beat - Finviz
Shareholders that lost money on DexCom, Inc.(DXCM) Urged to Join Class ActionContact Levi & Korsinsky to Learn More - Morningstar
Carillon Eagle Mid Cap Growth Fund’s Views on Dexcom (DXCM) - Insider Monkey
Evercore Initiates Coverage on DexCom With In Line Rating, $68 Price Target - MarketScreener
Bragar Eagel & Squire, P.C. Urges DexCom and Wildermuth Investors to Contact the Firm Regarding Their Rights - GlobeNewswire
Elanco, AMN Healthcare Services, Brookdale, DexCom, and Addus HomeCare Shares Skyrocket, What You Need To Know - TradingView
Investors in DexCom, Inc. Should Contact The Gross Law Firm Before December 26, 2025 to Discuss Your RightsDXCM - Your Wyoming Link
DexCom, Inc. (DXCM) Investors: December 26, 2025 Filing - GlobeNewswire
DexCom, Inc. Class Action: The Gross Law Firm Reminds - GlobeNewswire
Lowey Dannenberg Notifies DexCom, Inc. (“DexCom” or the - GlobeNewswire
Ademi & Fruchter LLP Investigates Claims of Securities Fraud against DexCom, Inc. - PR Newswire
SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A - GlobeNewswire
DXCM Stock Falls Despite FDA Clearance for Dexcom Smart Basal - MSN
ROSEN, GLOBAL INVESTOR COUNSEL, Encourages DexCom, Inc. - GlobeNewswire
Kessler Topaz Meltzer & Check, LLP Notifies DexCom, Inc. Investors of Upcoming Deadline in Securities Fraud Class Action Lawsuit - The Globe and Mail
DXCM INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Reminds Stockholders of DexCom, Inc. to Contact the Firm Today! - ACCESS Newswire
DXCM Announcement: Kessler Topaz Meltzer & Check, LLP Encourages DexCom, Inc. (DXCM) Investors to Contact the Firm About Securities Fraud Class Action Lawsuit - The Malaysian Reserve
Bank Julius Baer & Co. Ltd Zurich Sells 8,697 Shares of DexCom, Inc. $DXCM - Defense World
AbbVie, Biogen, BioMarin Pharmaceutical, DexCom, and Abbott Laboratories Stocks Trade Up, What You Need To Know - Yahoo Finance
DXCM INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that DexCom, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
DXCM LAWSUIT ALERT: Levi & Korsinsky Notifies DexCom, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - NewMediaWire
DexCom, Inc. Sued for Securities Law ViolationsContact the DJS Law Group to Discuss Your RightsDXCM - MarketScreener
DexCom Inc. Stock Underperforms Thursday When Compared To Competitors - 富途牛牛
DXCM SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that DexCom, Inc. Shareholders with Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
ROSEN, SKILLED INVESTOR COUNSEL, Encourages DexCom, Inc. - GlobeNewswire
Dexcom Inc Stock (DXCM) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.21%
0.12%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):